Short answer
Twist Bioscience Corp (TWST) filed its Q4 2025 10-Q quarterly report on Feb 2, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $104M (up 16.9% year over year) with net income of −$31M.
Q4 2025 key financials · XBRL
- Revenue
- $104M
- +16.9% YoY
- Net income
- −$31M
- +3.4% YoY
- Operating margin
- -31.7%
- EPS (diluted)
- −$0.50
- +5.7% YoY
Source: XBRL data from the Twist Bioscience Corp (TWST) Q4 2025 10-Q on SEC EDGAR. USD.
Twist Bioscience Corp Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes in risk factors from 10-K; risks primarily forward-looking statement disclaimers
- Regulatory risk: potential liability from undisclosed future acquisitions, mergers, or joint ventures
- Operational risk: reliance on management’s expectations amid uncertainties affecting results and plans
- Market risk: changes in competitive landscape could materially affect results, circumstances unknown
- Financial risk: no updates on liquidity, debt, currency exposure noted in this filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Twist Bioscience Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.